Actuate Therapeutics (NASDAQ:ACTU) Raised to “Hold” at Wall Street Zen

Actuate Therapeutics (NASDAQ:ACTU) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Friday, March 27th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Actuate Therapeutics Price Performance

Shares of ACTU stock opened at $2.48 on Friday. Actuate Therapeutics has a 1 year low of $2.05 and a 1 year high of $11.99. The stock’s 50 day simple moving average is $3.54 and its two-hundred day simple moving average is $5.57. The company has a market cap of $58.80 million, a PE ratio of -2.36 and a beta of 0.85.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ACTU. BIOS Capital Management LP grew its stake in shares of Actuate Therapeutics by 0.9% during the third quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock valued at $67,234,000 after buying an additional 84,917 shares during the last quarter. Voss Capital LP lifted its stake in shares of Actuate Therapeutics by 45.0% during the 4th quarter. Voss Capital LP now owns 1,300,000 shares of the company’s stock worth $7,956,000 after acquiring an additional 403,722 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Actuate Therapeutics by 19.5% during the 3rd quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock valued at $2,114,000 after acquiring an additional 51,546 shares during the period. Geode Capital Management LLC boosted its holdings in Actuate Therapeutics by 42.9% during the 4th quarter. Geode Capital Management LLC now owns 207,744 shares of the company’s stock valued at $1,271,000 after acquiring an additional 62,332 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in Actuate Therapeutics in the 4th quarter valued at $579,000.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.